Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by llasorsa
Group name EquipeMY
Item Type Journal Article
Title Why Is Wnt/?-Catenin Not Yet Targeted in Routine Cancer Care?
Creator de Pellegars-Malhortie et al.
Author Auriane de Pellegars-Malhortie
Author Laurence Picque Lasorsa
Author Thibault Mazard
Author Fabien Granier
Author Corinne Prévostel
Abstract Despite significant progress in cancer prevention, screening, and treatment, the still limited number of therapeutic options is an obstacle towards increasing the cancer cure rate. In recent years, many efforts were put forth to develop therapeutics that selectively target different components of the oncogenic Wnt/?-catenin signaling pathway. These include small molecule inhibitors, antibodies, and more recently, gene-based approaches. Although some of them showed promising outcomes in clinical trials, the Wnt/?-catenin pathway is still not targeted in routine clinical practice for cancer management. As for most anticancer treatments, a critical limitation to the use of Wnt/?-catenin inhibitors is their therapeutic index, i.e., the difficulty of combining effective anticancer activity with acceptable toxicity. Protecting healthy tissues from the effects of Wnt/?-catenin inhibitors is a major issue due to the vital role of the Wnt/?-catenin signaling pathway in adult tissue homeostasis and regeneration. In this review, we provide an up-to-date summary of clinical trials on Wnt/?-catenin pathway inhibitors, examine their anti-tumor activity and associated adverse events, and explore strategies under development to improve the benefit/risk profile of this therapeutic approach.
Publication Pharmaceuticals (Basel, Switzerland)
Volume 17
Issue 7
Pages 949
Date 2024-07-16
Journal Abbr Pharmaceuticals (Basel)
Language eng
DOI 10.3390/ph17070949
ISSN 1424-8247
Library Catalog PubMed
Extra PMID: 39065798 PMCID: PMC11279613
Tags ADC, cancer therapy, drug combination, drug profiling, nanovectorization, small molecule inhibitors, Wnt/?-catenin
Date Added 2024/10/10 - 16:16:37
Date Modified 2024/10/10 - 16:16:37
Notes and Attachments PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés